Pharmaceutical Product Development Inc
Pharmaceutical Product Development — Q3 2010 Earnings Presentation
5 slides from Pharmaceutical Product Development's earnings presentation, Oct 26, 2010
Slide 1: Business Segment Review Third Quarter 2010 Earnings Call
Business Segment Review Third Quarter 2010 Earnings Call October 27, 2010 Exhibit 99.2
Slide 2: Safe Harbor
Safe Harbor This presentation includes selected non-GAAP financial measures. For a presentation of and reconciliation to the most directly comparable GAAP financial measures, go to the link titled “GAAP/Non-GAAP Reconciliation Presentation” under Presentations & Events in the Investors section of PP
Slide 3: Business Segments
Business Segments * Phase II-IV Clinical Trial Management - Project Management - Clinical Trial Monitoring - Data Management - Biostatistics - Regulatory Affairs - Pharmacovigilance - Late-Stage Phase I Clinic cGMP Bioanalytical Global Central Labs Vaccines & Biologics BioDuro / Discovery Services *
Slide 4: Net Revenue by Segment (Non-GAAP, in Millions)
Net Revenue by Segment (Non-GAAP, in Millions*) Q1 Q2 Q3 Q4 Q1 Q2 Q3 $268.1 $260.1 $250.0 $256.7 $249.3 $255.4 $260.3 % of Total 79.9% 78.8% 79.2% 78.2% 77.0% 76.5% 76.7% $67.3 $70.1 $65.9 $71.4 $74.5 $78.3 $79.0 % of Total 20.1% 21.2% 20.8% 21.8% 23.0% 23.5% 23.3% Total (Formerly Development Segmen
Slide 5: Income from Operations by Segment (Non-GAAP, in Millions)
Income from Operations by Segment (Non-GAAP, in Millions*) Q1 Q2 Q3 Q4 Q1 Q2 Q3 $51.9 $48.0 $47.0 $41.0 $31.7 $34.6 $47.2 Operating Margin % 19.3% 18.5% 18.8% 16.0% 12.7% 13.6% 18.1% $15.4 $15.2 $13.2 $12.8 $10.1 $12.3 $13.5 Operating Margin % 22.9% 21.7% 20.0% 17.9% 13.5% 15.6% 17.1% Total (Formerl
Pharmaceutical Product Development — Q3 2010 Earnings Presentation on 6ix